Clinical DevelopmentThe company is expanding its research frontier, initiating preclinical studies for EQ302 in gastrointestinal and cutaneous diseases, showcasing a broadening therapeutic pipeline.
Drug EfficacyItolizumab demonstrates a competitive Overall Renal Response rate in Lupus Nephritis, indicating strong potential in a high-need medical area.
Financial HealthWith a potential $33M payment from Ono Pharmaceuticals, the company is poised for financial stability, potentially extending its cash runway significantly.